Clinical Study
Subconjunctival Bevacizumab Injection in Glaucoma Filtering Surgery: A Case Control Series
Table 5
Characteristics of patients with branch vein occlusion (BRVO) in the subconjunctival bevacizumab (SCB) group.
| Patient | Age (years) | Sex | Medical history | Eye | Diagnosis | Preoperative VA | Type of surgery | Postoperative interventions | Onset of BRVO | Treatment | Final VA | Final IOP (mm Hg) |
| 1 | 73 | F | None | OS | POAG | 20/40 | Phacotrab. | Needling goniopuncture suture lysis SCB | 14.8 weeks postsurgery 8.8 weeks after SCB | Focal laser | 20/30 | 8 |
| 2 | 81 | M | HTN BRVO OD | OD | POAG | 20/50 | Phaco-NPGS | SCB goniopuncture suture lysis | 7.8 weeks postsurgery 6.8 weeks after SCB | IVTA | 20/150 | 10 |
| 3 | 80 | M | Hyperchol. | OS | POAG | 20/40 | Phacotrab. | SCB | 9.7 weeks postsurgery 8.3 weeks after SCB | Focal laser | 20/40 | 14 |
|
|
HTN: hypertension; hyperchol.: hypercholesterolemia; POAG: primary open-angle glaucoma; phacotrab.: phacotrabeculectomy; NPGS: nonpenetrating glaucoma surgery; SCB: subconjunctival injection of bevacizumab; IVTA: intravitreal injection of triamcinolone acetonide; VA: visual acuity.
|